Testosterone replacement therapy in the setting of prostate cancer treated with radiation

A W Pastuszak; A M Pearlman; G Godoy; B J Miles; L I Lipshultz; M Khera

doi:10.1038/ijir.2012.29

Back

Testosterone replacement therapy in the setting of prostate cancer treated with radiation

Journal article

Peer reviewed

Testosterone replacement therapy in the setting of prostate cancer treated with radiation

A W Pastuszak, A M Pearlman, G Godoy, B J Miles, L I Lipshultz and M Khera

International journal of impotence research, Vol.25(1), pp.24-28

01/2013

DOI: 10.1038/ijir.2012.29

PMID: 22971614

View Online

Abstract

A lack of consensus and few data support testosterone replacement therapy (TRT) in hypogonadal men who have been treated for prostate cancer (CaP), particularly those who have received radiation therapy. We performed retrospective review of 13 hypogonadal men with CaP, treated with brachytherapy or external beam radiotherapy who were subsequently treated with testosterone (T) between 2006 and 2011. Serum T, free T (FT), estrogen (E), sex hormone-binding globulin (SHBG), prostate-specific antigen (PSA), hemoglobin (Hgb) and hematocrit (Hct) values were evaluated approximately every 3 months after TRT initiation up to 67 months of follow-up. Prostate biopsies demonstrated four men with Gleason (Gl) 6, 7 with Gl 7 and 2 with Gl 8 disease. Median (interquartile range) age at TRT initiation was 68.0 (62.0-77.0) years, initial T 178.0 (88.0-263.5) ng dl(-1), FT 10.1 (5.7-15.0) pg ml(-1) and PSA 0.30 (0.06-0.95) ng ml(-1). Median follow-up after TRT initiation was 29.7 months (range 2.3-67.3 months). At median follow-up, a significant increase in mean T (368.0 (281.3-591.0) ng dl(-1), P=0.012) and SHBG were observed, with no significant increases in Hgb, Hct, E, FT, or PSA (0.66 (0.16-1.35) ng ml(-1), P=0.345). No significant increases in PSA or CaP recurrences were observed at any follow-up interval. TRT in the setting of CaP after treatment with radiation therapy results in a rise in serum T levels and improvement in hypogonadal symptoms without evidence of CaP recurrence or progression.

Hypogonadism - drug therapy

Prostatic Neoplasms - radiotherapy

Humans

Middle Aged

Male

Hormone Replacement Therapy

Prostate-Specific Antigen - blood

Neoplasm Grading

Aged

Retrospective Studies

Testosterone - blood

Hypogonadism - etiology

Brachytherapy - adverse effects

Prostatic Neoplasms - drug therapy

Testosterone - therapeutic use

Details

Title: Subtitle: Testosterone replacement therapy in the setting of prostate cancer treated with radiation
Creators: A W Pastuszak - Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
A M Pearlman
G Godoy
B J Miles
L I Lipshultz
M Khera
Resource Type: Journal article
Publication Details: International journal of impotence research, Vol.25(1), pp.24-28
DOI: 10.1038/ijir.2012.29
PMID: 22971614
NLM abbreviation: Int J Impot Res
ISSN: 0955-9930
eISSN: 1476-5489
Publisher: England
Language: English
Date published: 01/2013
Academic Unit: Urology
Record Identifier: 9984051868702771

Metrics

40 Record Views

71 Times Cited - Web of Science